Spots Global Cancer Trial Database for Cancer Genome Atlas of China:Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cancer Genome Atlas of China:Lung Cancer
Official Title: Cancer Genome Atlas of China:Lung Cancer
Study ID: NCT04266483
Conditions
Interventions
Study Description
Brief Summary: Based on 2500 lung cancer tumor tissue samples from about 40 clinical centers in China, the molecular typing of lung cancer in China will be figured out by high throughput sequencing, which will provide the basis for the follow-up research and development of new drugs as well as the guidance of treatment.
Detailed Description: This project will establish a standardized procedure of lung cancer sample collection, transportation, storage, detection, bioinformatics analysis and result judgment, so as to draw up the gene map of advanced lung cancer in China, and provide an important basis for the research and development of new drugs and the guidance of treatment. Firstly, 2500 cases of lung cancer tumor tissue samples will be collected according to the Inclusion Criteria. Secondly，samples will be sequenced through high throughput sequencing by ChosenMed Technology (Beijing) Co., Ltd., according to the strict process. Panel sequencing of the samples will be carried out through Illumina platform. After targeting Panel sequencing, four types of mutations including point mutation, insertion deletion, gene fusion and copy number variation will be detected, and tumor mutation burden as well as microsatellite instability will be evaluated. Combined with the bioinformatics analysis and sequencing results of the samples, the gene map of lung cancer in China will be drawn up, and the specific multigene panel of lung cancer for the Chinese population will be established as the basis for the subsequent clinical screening of molecular markers related to targeting therapy, immunotherapy and prognosis. Thirdly, patients will be followed up on the information related to treatment after sequencing. According to the genetic information of the patients, the curative effect and prognosis of the patients will be followed up every three to six months. The follow-up time includes at least the first treatment plan after the patients' detection, which may continue until the final survival time of the patients, and explore the molecular markers and combinations that can affect the curative effect and prognosis of patients with lung cancer. Finally, the clinical data and specimen information of patients will be managed and analyzed by Excel. Multivariate Cox regression analysis will be used to explore the clinical, pathological and molecular markers that affect the prognosis and curative effect of lung cancer, and draw the survival curve with the statistically significant indicators so as to provide reliable statistical results for the following clinical guidance.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Guangzhou Institute of Respiratory Health, Guangzhou, Guangdong, China
Affiliated Hospital of Hebei University, Baoding, Hebei, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
The Second Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
The Second Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
The First Hospital of Jilin University, Changchun, Jilin, China
Sino-Japan Friendship Hospital, Jilin University, Changchun, Jilin, China
The Third Hospital of Jilin University, Changchun, Jilin, China
The First Hospital Affiliated to Dalian Medical University, Dalian, Liaoning, China
General Hospital of the Northern Theater of Chinese PLA, Shenyang, Liaoning, China
The First Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Qilu Hospital, Shandong University, Jinan, Shandong, China
Shandong Provincial Hospital, Jinan, Shangdong, China
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine (Binjiang District), Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medcine (Headquarters), Hangzhou, Zhejiang, China
Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China
The Fourth Medical Center of PLA General Hospital, Beijing, , China
Beijing Friendship Hospital, Capital Medical University, Beijing, , China
Xuanwu Hospital,Beijing, Beijing, , China
Air Force Specialized Medical Center, Beijing, , China
Air Force Specialized Medical Center, Beijing, , China
Peking University Cancer Hospital, Beijing, , China
The Seventh Medical Center of PLA General Hospital, Beijing, , China
Beijing Hospital, Beijing, , China
Chinese PLA General Hospital, Beijing, , China
Chinese PLA General Hospital, Beijing, , China
Beijing Chest Hospital, Capital Medical University, Beijing, , China
Renji Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, , China
Lung Hospital Affiliated to Shanghai Tongji Medical University, Shanghai, , China
General Hospital of Tianjin Medical University, Tianjin, , China
Contact Details
Name: Xiuyi Zhi, M.D.
Affiliation: Xuanwu Hospital, Beijing
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
